Exact Sciences Reports First-Quarter 2013 Financial Results, Announces Addition to Board of Director
Exact Sciences Reports First-Quarter 2013 Financial Results, Announces Addition to Board of Directors
Exact reported total revenues of $1.0 million for the first quarter of 2013, compared to $1.0 million for the first quarter of 2012.
Exact reported a net loss of ($10.9) million, or ($0.17) a share, for the first quarter of 2013. The company had a net loss of ($10.6) million, or ($0.19) a share, for the same period of 2012.
Operating expenses for the quarter ended March 31, 2013, were $11.9 million, compared to $11.7 million for the first quarter of 2012.
Exact ended the first quarter of 2013 with cash, cash equivalents and marketable securities of $95.5 million, compared to $108.1 million at Dec. 31, 2012.
"We are very pleased to have concluded our DeeP-C pivotal clinical trial and announced strong preliminary, top-line trial results," said Kevin T. Conroy, the company's president and chief executive. "We are extremely pleased with Cologuard's achievement of superiority to the fecal immunochemical test or FIT for both cancer and pre-cancer sensitivity. We intend to seek FDA approval for claims of superiority over the FIT test for both cancer and pre-cancerous polyp detection."
Exact also announced that Thomas D. Carey, 51, has joined its board of directors. Mr. Carey brings to the board more than 20 years experience and expertise in the life sciences industry. He is a member at Spencer Stuart, a global executive search firm, where he is responsible for leading the firm's global efforts to provide board services to health care companies.
Prior to joining Spencer Stuart in 2010, Mr. Carey served as a partner and co-head of Russell Reynolds Associates' global life sciences practice. Before entering the search industry, he served as an investment banker and chief financial officer for both public and private health care and information technology companies. Mr. Carey earned a bachelor's degree from the College of the Holy Cross and a master's degree from Northwestern University's Kellogg School of Management.
"Tom is an outstanding addition to Exact's board of directors," Mr. Conroy said. "His experience in health care gives him a unique perspective of the field and what makes a company in our highly competitive industry great. We look forward to the benefit of Tom's expertise as we continue to make strong progress towards commercializing Cologuard."
First-Quarter Conference Call & Webcast
Company management will host a conference call and webcast on Wednesday, May 1, 2013, at 10 a.m. ET to discuss first-quarter results. The webcast will be available at www.exactsciences.com. Domestic callers should dial 877-212-6082 and international callers should dial 707-287-9332. An archive of the webcast and a replay of the conference call will be available at www.exactsciences.com or by calling 855-859-2056 domestically or 404-537-3406 internationally. The access code for the conference call and replay is 56685244. The conference call, webcast and replay are open to all interested parties.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company's website at www.exactsciences.com.
Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections.Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms.Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, anticipated results of our pivotal clinical trial, expectations concerning our ability to secure FDA approval of our Cologuard test, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy.Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q.We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
|EXACT SCIENCES CORPORATION|
|Selected Unaudited Financial Information|
|Condensed Statements of Operation Data|
|(Amounts in thouands, except per share data)|
|Three Months Ended|
|Research and development||7,526|
|General and administrative||2,648|
|Sales and marketing||1,759||594|
|Loss from operations||(10,897||)||(10,702||)|
|Net loss per share - basic and diluted||$||(0.17||)||$||(0.19||)|
Weighted average common shares outstanding - basic and diluted
|EXACT SCIENCES CORPORATION|
|Selected Unaudited Financial Information|
|Condensed Balance Sheet Data|
|(Amounts in thousands)|
|March 31,||December 31,|
|Cash and cash equivalents||$||8,053||$||13,345|
|Prepaid expenses and other current assets||1,067||593|
|Property and equipment, net||3,442||3,405|
|Liabilities and stockholders' equity|
|Total current liabilities||$||9,165||$||11,455|
|Long term debt||1,000||1,000|
|Long term accrued interest||68||63|
|Capital lease obligation, less current portion||625||711|
|Deferred license fees, less current portion||-||295|
|Total stockholders' equity||89,133||98,595|
|Total liabilities and stockholders' equity||$||99,991||$||112,119|
The Luminis Group, Ltd. for Exact Sciences Corp.
KEYWORDS: United States North America Wisconsin
The article Exact Sciences Reports First-Quarter 2013 Financial Results, Announces Addition to Board of Directors originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.